ArticleAmerican journal of preventive cardiology2022
Early diagnosis and treatments in childhood are associated with better prognosis in patients with familial hypercholesterolemia.
Article in American journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia.Journal of atherosclerosis and thrombosis · 2026Article
- Significance of Clinical and Genetic Signatures of Familial Hypercholesterolemia Among Patients With Severe Hypercholesterolemia.JACC. Advances · 2025Article
- Oligogenic Familial Hypercholesterolemia Treated by Combination Therapy of Statin, Ezetimibe, PCSK9 Inhibitor, and Lomitapide.Internal medicine (Tokyo, Japan) · 2025Article
- Assessments of Atherosclerosis and Treatment Strategies for Heterozygous Familial Hypercholesterolemia.Journal of atherosclerosis and thrombosis · 2025Review
- Triple Assessments of Atherosclerosis in Patients With Heterozygous Familial Hypercholesterolemia.JACC. Asia · 2025Article
- Gender Disparity in Lipid Testing Among Over 0.5 Million Adults from Pakistan: Females are Tested Much Later Despite Higher LDL-Cholesterol Levels.Global heart · 2025Article
- Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia.Journal of atherosclerosis and thrombosis · 2025Article
- The Importance of Genetic Testing for Familial Hypercholesterolemia: A Pediatric Pilot Study.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia.JACC. Case reports · 2024Article
- Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?Life (Basel, Switzerland) · 2024Review
- Impact of the severe familial hypercholesterolemia status on atherosclerotic risks.Scientific reports · 2023Article
- Coronary Artery and Carotid Artery Plaques in Patients With Heterozygous Familial Hypercholesterolemia.JACC. Advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The early diagnosis and treatment initiation for children with familial hypercholesterolemia (FH) has been recommended in guidelines. However, there is limited data on the impact of early treatments on the prognosis of children with FH. To investigate if the early initiation of lipid-lowering therapies among Japanese pediatric patients with FH reduced the occurrence of cardiovascular disease (CVD) events in them. Methods: We retrospectively investigated the occurrence of CVD events (myocardial infarction, unstable angina, or coronary artery revascularization) in patients with FH ( Results: The median follow-up duration was 12.6 [9.5-17.9] years. The baseline LDL cholesterol level, 239 mg/dL, dropped to 112 mg/dL with the treatments. The Achilles tendon thickness was significantly lower in children than that of adults (7.2 vs. 8.9 mm, Conclusion: The likelihood of CVD events in those with FH diagnosed and treated in childhood is low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.